new glp-1 drug Drugs from the Gray Market New GLP-1 drugs could suppress
Description
Gastrointestinal symptoms: nausea (20%), diarrhea (15%), vomiting (11%), constipation (6%), dyspepsia (6%), abdominal pain (5%), eructation (4%), gastroesophageal reflux disease (3%), abdominal distension (2%) and flatulence (2%)
Efficacy and safety of oral orforglipron in patients with type 2 diabetes: A multicentre, randomised, dose-response, phase 2 study
Alfaris said gastrointestinal adverse events were more common with orforglipron than placebo and were consistent with those seen in other incretin-based drugs
Clinical outcomes by albuminuria status with dulaglutide versus insulin glargine in participants with diabetes and CKD: AWARD-7 exploratory analysis
Consistent with earlier studies, side effects emerged as the most commonly cited reason for discontinuation, regardless of medication indication
Gloy VL, Briel M, Bhatt DL, Kashyap SR, Schauer PR, Mingrone G, et al
